drugset
drugset / Trial / NCT04217720

SNS-301 Monotherapy in High Risk MDS and CMML

NCT04217720 ↗

Phase 2 Withdrawn Sensei Biotherapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.

Timeline

Start
2020-04-01
Primary completion
2022-01-01
Completion
2023-01-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject SNS-301 Unknown 1e+11 unknown Other

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome